Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder

Creative Commons License

Pittock S. J., Berthele A., Fujihara K., Kim H. J., Levy M., Palace J., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.381, no.7, pp.614-625, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 381 Issue: 7
  • Publication Date: 2019
  • Doi Number: 10.1056/nejmoa1900866
  • Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.614-625
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Neuromyelitis optica spectrum disorder is a relapsing inflammatory disorder of the central nervous system. Two thirds of patients have antibodies against aquaporin-4, and CNS damage is complement dependent. The inhibitor of terminal complement C5 cleavage, eculizumab, reduced relapses of NMOSD.